Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | PLD2 | O14939 | 1/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1285606 | 0.98 | MAPK1 (0.49) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL18511940 | 0.90 | BACE1 (0.53) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL30890425 | 0.90 | BACE1 (0.53) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL29859914 | 0.90 | BACE1 (0.53) | BACE1MAPK1TP53CYP3A4MAPT | |
| Trifluoroacetic Acid SCHEMBL28528760 | 0.88 | TP53 (0.47) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL5516089 | 0.86 | MAPK1 (0.49) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL4848524 | 0.86 | MAPK1 (0.49) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL13110266 | 0.83 | MAPK1 (0.47) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL23795729 | 0.82 | BACE1 (0.39) | BACE1MAPK1TP53CYP3A4MAPT | |
| SCHEMBL30825002 | 0.81 | SIGMAR1 (0.49) | BACE1MAPK1TP53CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-108368087-B | 2, 4-dihydroxy-nicotinamide as APJ agonists | 百时美施贵宝公司 | 2022-04-12 | — | — | CN | claimed |
| EP-3717488-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | Dart NeuroScience, LLC (US) | 2020-10-07 | — | — | EP | claimed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | claimed |
| EP-4747251-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025019479-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024229262-A1 | NARROW-SPECTRUM ANTIBIOTIC COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2024-11-07 | — | — | WO | disclosed |
| US-12006325-B2 | Substituted furanopyrimidine compounds as PDE1 inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-06-11 | — | — | US | disclosed |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2007146349-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007077122-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
| US-6436962-B1 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS; RELIEF FROM BENIGN PROSTATIC HYPERPLASIA BY LESS HINDERED URINE FLOW BY RELAXING SMOOTH MUSCLE TISSUE; WITH A TESTOSTERONE 5-ALPHA REDUCTASE INHIBITOR, FINASTERIDE; ACUTE AND CHRONIC RELIEF | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-6326372-B1 | BENIGN PROSTATE HYPERPLASIA | MERCK & CO., INC. | 2001-12-04 | — | — | US | disclosed |
| US-6316437-B1 | ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001045707-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-4558049-A | Antipsycotic benzoxazines | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006325-B2 | Substituted furanopyrimidine compounds as PDE1 inhibitors | PDE4A, PDE5A, PDE3A | BACE1 319/4885MAPK1 221/4885TP53 349/4885 |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | BACE1 319/4885MAPK1 221/4885TP53 349/4885 |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | BACE1 319/4885MAPK1 221/4885TP53 349/4885 |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | AVPR2, OXTR, AVPR1A | BACE1 3511/4885MAPK1 3956/4885TP53 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.